Type I reaction of Hansen's disease with exposure to adalimumab: A case report

Oberstein, Elana M.; Kromo, Olga; Tozman, Elaine C.

doi:10.1002/art.23815

Cited by 23 publications

(20 citation statements)

References 16 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Infectious complications observed while undergoing adalimumab therapy include serious pulmonary bacterial infections, TB, candidiasis, cytomegalovirus (CMV) infection, toxoplasmosis, and nocardiosis (27,44). One case of reversal reaction with leprosy has been reported (122). Early trials and safety data analyses have been inconsistent in showing a link between adalimumab and a higher risk of serious infection (101; Humira package insert).…”

mentioning

confidence: 99%

Infectious Complications Associated with Monoclonal Antibodies and Related Small Molecules

Salvaña

Salata

2009

Clin Microbiol Rev

View full text Add to dashboard Cite

SUMMARY Biologics are increasingly becoming part of routine disease management. As more agents are developed, the challenge of keeping track of indications and side effects is growing. While biologics represent a milestone in targeted and specific therapy, they are not without drawbacks, and the judicious use of these “magic bullets” is essential if their full potential is to be realized. Infectious complications in particular are not an uncommon side effect of therapy, whether as a direct consequence of the agent or because of the underlying disease process. With this in mind, we have reviewed and summarized the risks of infection and the infectious disease-related complications for all FDA-approved monoclonal antibodies and some related small molecules, and we discuss the probable mechanisms involved in immunosuppression as well as recommendations for prophylaxis and treatment of specific disease entities.

show abstract

mentioning

confidence: 99%

Infectious Complications Associated with Monoclonal Antibodies and Related Small Molecules

Salvaña

Salata

2009

Clin Microbiol Rev

View full text Add to dashboard Cite

show abstract

“…5 Recently, Oberstein et al reported on a patient from the Amazon region with symmetrical polyarthritis and inadequate response to corticosteroids and MTX, who developed diffuse macular rash with biopsy compatible with tuberculoid leprosy after using ADA. 6 Our patient was treated with IFX for almost two years and he did not develop significant adverse reaction, but, two weeks after it was substituted for ADA, he developed cutaneous lesions characteristic of lepromatous leprosy. It is known that the natural history of leprosy is characterized by a slow course until the development of skin lesions; however, in this case, an intimate temporal correlation between the modification of the anti-TNF agent and the cutaneous lesion was observed.…”

Section: Discussionmentioning

confidence: 62%

“…This finding suggests that the regulatory activity of the soluble TNF receptor is partially hindered in patients with lepromatous leprosy, but not in other clinical types of the disease. 11 In the three cases reported in the literature, 5,6 the differential diagnosis between RA and leprosy-related arthritis remained uncertain. On the other hand, in the case reported here, the patient had erosive and symmetrical polyarthritis of small and large joints five years before the development of leprosy, developing severe ankylosis of hips and shoulders, articular findings that are not observed in leprosy patients.…”

Section: Discussionmentioning

confidence: 99%

Hanseníase virchowiana associada ao uso de inibidor do fator de necrose tumoral α: relato de caso

Freitas¹,

Machado²,

Andrigueti³

et al. 2010

Rev. Bras. Reumatol.

View full text Add to dashboard Cite

TNF blockers have been used in the treatment of several types of chronic inflammatory arthritis, especially rheumatoid arthritis. However, many doubts regarding the safety and high risk of infectious diseases in these patients remain. The main objective of this report was to present a case of lepromatous leprosy in a rheumatoid arthritis patient using TNF blockers. The development of adverse events should be rigorously observed, especially those related to infectious agents. Thus, appropriate investigation of skin lesions in patients receiving anti-TNFa therapy is recommended, as the initial clinical manifestation may be unusual, particularly in endemic regions in Brazil.

show abstract

“…Acute arthritis in leprosy usually occurs as part of lepra reactions – typically, type I reactions, in patients with borderline or paucibacillary disease or type II reactions in patients with lepromatous leprosy 9. Also a chronic, relapsing, symmetrical, inflammatory, peripheral polyarthritis affecting primarily the wrists, metacarpal and proximal interphalangeal joints of the hands with a RA – like distribution associated with leprosy has been described 10 11…”

Section: Discussionmentioning

confidence: 99%

“…Recently, some cases of leprosy have been reported among patients born and resident in countries without leprosy, after treatment with anti-TNF α agents – infliximab and adalimumab 9 19…”

Section: Discussionmentioning

confidence: 99%